Quotient Bioscience

Quotient Bioscience was a prominent drug development services group based in the United Kingdom, serving the global pharmaceutical and biotechnology sectors. The company was structured into two main divisions: Quotient Clinical, which focused on early-stage clinical drug development, and Quotient Bioresearch, which provided bioanalytical and radiolabelling services. It pioneered the "Translational Pharmaceutics" platform, an innovative approach that integrates drug product manufacturing and clinical testing to streamline the development process. Over time, the group's components were divested, with the clinical arm evolving into the independent CDMO Quotient Sciences and the radiochemistry business being acquired by Pharmaron. The group played a significant role in accelerating the transition from pre-clinical development to clinical proof-of-concept for its global client base.